Editas Medicine (EDIT) Prices 3.5M Share Common Offering at $66/Sh

Editas Medicine, Inc. (NASDAQ: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. Gross proceeds from the offering are expected to be approximately $231.0 million. Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock on the same terms and conditions. All of the shares in the offering are to be sold by Editas Medicine. The offering is expected to close on or about January 25, 2021, subject to customary closing conditions.

J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. Cowen and Credit Suisse are acting as book-runners.

An automatically effective shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on March 12, 2018. The offering is being made only by means of a prospectus and prospectus supplement that form part of the registration statement.

You May Also Be Interested In

• Alliance Laundry principal stockholder prices 22.55M share offering
• Cosmos Health posts 29% revenue rise in Q2 but net loss widens
• Cizzle Brands files SEC Form F-10, plans U.S. exchange listing